Overcome the Challenge of Treating Unmet Medical Needs Caused by Mitochondrial Dysfunction

Incorporating insights from leading academics and pioneering biotech, the Mitochondria-Targeted Drug Development Summit will specifically focus on targeting mitochondrial dysfunction to develop therapies for chronic diseases caused by mitochondrial DNA mutation/nuclear DNA mutations, muscle dystrophy diseases/muscle loss, metabolic disorders, neurodegenerative disease, and conditions linked to oxidative damage.

From basic research to the clinic, this year’s meeting will examine novel preclinical animal modelling solutions specifically targeting mitochondria, deliver an update on the current leading clinical trials showcasing mitochondrial transfer, mutations, metabolism, quality control, biogenesis, and peroxidation/ oxidation, along with dedicated sessions on the significance on informatics and data sharing for precision medicine.

Join 80+ leading experts as they navigate common challenges and opportunities for treating unmet medical needs caused by mitochondrial dysfunction. Mitobridge/Astellas, Minovia Therapeutics, Abliva, GenSight Biologics, Stealth Biotherapeutics and many more will unite drive to better understand how to create effective and scalable mitochondrial therapies. Register your interest for 2023.

Great key speakers that touched on a broad range of subjects. It was very informative and interesting to see how many disease areas mitochondria is being targeted.
Scientific Associate, Novartis

---

Good overview of a developing field. Learned a lot and found colleagues that I will be reaching out to. It was definitely worthwhile attending.
Director - Clinical Research, Revalesio Corporation

---

Extremely exciting to learn about past and present efforts in the mito field. I enjoyed the large breath of expertise and the high quality of the presentations. I particularly enjoyed the lively and informative panels.
Founder, Frederik's Foundation

2022 Expert Speakers Included

Joseph Sarret

President & Chief Executive Officer

CohBar

Natalie Yivgi-Ohana

Co-Founder & Chief Executive Officer

Minovia

Reenie McCarthy

Chief Executive Officer

Stealth Biotherapeutics

Selvaraj Nataraja

Senior Director, Translational Research

Mitobridge/Astellas

Bärbel (Barb) Rohrer, Ph.D.

Co-Founder & Chief Scientific Officer

MitoChem Therapeutics

David Marcinek

Professor of Radiology, Adjunct of Bioengineering and Laboratory Medicine and Pathology

University of Washington Medical School

David Schaaf

Vice President, US Medical Affairs, Senior Medical Officer

Zogenix

Douglas Wallace

Director - CME, The Children's Hospital of Philadelphia Research Institute & Professor, Hospital of the University of Pennsylvania